Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2354-2364
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2354
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2354
Figure 1 Rate of patients achieving the different therapeutic endpoints after 12 wk of anti-tumor necrosis factor therapy in 40 patients with Crohn’s disease.
CDAI: Crohn’s disease activity index; CRP: C-reactive protein; Fcal: Faecal calprotectin; TNF: Tumor necrosis factor.
- Citation: Sollelis E, Quinard RM, Bouguen G, Goutte M, Goutorbe F, Bouvier D, Pereira B, Bommelaer G, Buisson A. Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease. World J Gastroenterol 2019; 25(19): 2354-2364
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2354.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2354